Effective drugs in liver cancer
The most effective drugs in liver cancer chemotherapy are doxorubicin (doxorubicin), 5-fluorouracil and cisplatin. But usually these drugs can only shrink the tumor, and the response usually does not last long, and has little effect on the life extension of patients.
Due to the poor response of systemic chemotherapy, doctors tried to inject chemotherapy drugs directly into the hepatic artery and directly into the liver. This technique is called hepatic artery infusion (HAI). But a healthy liver will decompose most drugs. Compared with systemic chemotherapy, this pair of chemotherapy methods is better and does not increase side effects. The most commonly used drugs include fluorouridine (FUDR), cisplatin, mitomycin C and doxorubicin. Early research found that HAI can effectively control tumors, but more research is still needed. However, this technique is not useful for all patients because it requires surgery to insert the catheter into the hepatic artery, which is not feasible for many patients with liver cancer who cannot tolerate the operation.
Side effects of chemotherapy in liver cancer
The side effects of chemotherapy mainly depend on the dosage of medication and the time of taking the medication. Common side effects include: hair loss, mouth ulcers, loss of appetite, nausea and vomiting, diarrhea, increased risk of infection (low white blood cell count), easy bruising or bleeding (low platelet count), and fatigue (low red blood cell count). These side effects usually do not last very long and usually disappear after treatment. Doctors will also give patients appropriate medicines according to the actual situation to help them prevent or reduce side effects such as nausea and vomiting. In some cases, it may be necessary to reduce the dose of chemotherapy drugs, or it may be necessary to delay or stop treatment to avoid serious side effects.
Susan Hau is a distinguished researcher in the field of cancer cell therapy, with a particular focus on T cell-based approaches and cancer vaccines. Her work spans several innovative treatment modalities, including CAR T-cell therapy, TIL (Tumor-Infiltrating Lymphocyte) therapy, and NK (Natural Killer) cell therapy.
Hau's expertise lies in cancer cell biology, where she has made significant contributions to understanding the complex interactions between immune cells and tumors.
Her research aims to enhance the efficacy of immunotherapies by manipulating the tumor microenvironment and exploring novel ways to activate and direct immune responses against cancer cells.
Throughout her career, Hau has collaborated with leading professors and researchers in the field of cancer treatment, both in the United States and China.
These international experiences have broadened her perspective and contributed to her innovative approach to cancer therapy development.
Hau's work is particularly focused on addressing the challenges of treating advanced and metastatic cancers. She has been involved in clinical trials evaluating the safety and efficacy of various immunotherapy approaches, including the promising Gamma Delta T cell therapy.
